MDC-CAR-BCMA001 (BCMA directed CAR T-cells) clinical trials

A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies

This early-stage study is testing a new cell therapy called MDC-CAR-BCMA001. It aims to find the safest dose for people with certain types of blood cancers, like some lymphomas and multiple myeloma, that have come back or not responded to other treatments.